FRANCES BROWN: Open Payments
NPI 1770352627 · PENSACOLA, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,995 in 163 payments from 22 companies in 2025. Trend: 2023 $0 · 2024 $2,667 · 2025 $3,995
Food & beverage: $3,739Education: $256
| Company | Payments | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 24 | $912 |
| AstraZeneca Pharmaceuticals LP | 28 | $732 |
| GENZYME CORPORATION | 21 | $423 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $396 |
| Amgen Inc. | 16 | $289 |
| GlaxoSmithKline, LLC. | 16 | $260 |
| Novartis Pharmaceuticals Corporation | 8 | $176 |
| Genentech USA, Inc. | 6 | $118 |
| Lilly USA, LLC | 4 | $113 |
| Blueprint Medicines Corporation | 5 | $110 |
Products named: DUPIXENT, TEZSPIRE, CUVITRU, FASENRA, AYVAKIT, AIRSUPRA, TRELEGY ELLIPTA, Xolair.
Industry payments across FL — which companies pay providers there.
